Cabaletta Bio
Develops engineered T-cell therapies for autoimmune disease, prioritizing rese-cel.
$3.18
After-hours close+0.07 (+2.25%)
At close$3.11(−7.99%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 51.93%84.68M sharesInsiders 0.78%1.28M sharesOther 47.29%77.10M shares
Shares outstanding 163.05M · Float 142.90M · 87.6% free float
Institutions13F, as of Mar 31, 2026
118 holders · 84.68M shares · 30 new positions · 63 increased · 27 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11.08M | 6.80% | +1.22M | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | 9.68M | 5.93% | 0 | May 15, 2026 |
| Jennison Associates LLC | 8.97M | 5.50% | +64.9K | May 6, 2026 |
| Adage Capital Partners GP, L.L.C. | 8.83M | 5.42% | 0 | May 15, 2026 |
| Millennium Management LLC | 5.90M | 3.62% | +3.17M | May 15, 2026 |
| Cormorant Asset Management, LP | 5.50M | 3.37% | +1.10M | May 15, 2026 |
| Vanguard Capital Management LLC | 4.03M | 2.47% | +4.03Mnew | May 15, 2026 |
| Two Sigma Investments, LP | 2.50M | 1.53% | +658.1K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Prudential Financial Inc | 11.40% | 24.27M | 13G | Jun 5, 2026 ↗ |
| Jennison Associates LLC | 11.40% | 24.27M | 13G | Jun 4, 2026 ↗ |
| T. Rowe Price Investment Management, Inc. | 10.20% | 9.86M | 13G | Feb 17, 2026 ↗ |
| Bain Capital Life Sciences Opportunities III, LP | 9.99% | 9.68M | 13G | Aug 14, 2025 ↗ |
| Adage Capital Management, L.P. | 9.99% | 9.00M | 13G | Aug 12, 2025 ↗ |
| Cormorant Asset Management, LP | 9.03% | 10.50M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.90% | 9.61M | 13G | Jul 27, 2026 ↗ |
| Norges Bank | 5.38% | 8.78M | 13G | Aug 12, 2026 ↗ |
| Millennium Management LLC | 5.30% | 5.13M | 13G | Feb 18, 2026 ↗ |
| Vanguard Capital Management | 5.08% | 8.30M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Steven Nichtberger | director, officer: President & CEO | 1.03M | 0.63% | Jan 21, 2026 |
| Mark Simon | director | 147.2K | 0.09% | Jan 21, 2026 |
| Gwendolyn Binder | officer: President, Science & Tech. | 31.3K | 0.02% | Jan 21, 2026 |
| Shawn Tomasello | director | 22.7K | 0.01% | Jan 21, 2026 |
| Steve Gavel | officer: Chief Commercial Officer | 22.2K | 0.01% | Jan 21, 2026 |
| David J. Chang | officer: Chief Medical Officer | 8.8K | 0.01% | Jan 21, 2026 |
| Michael Gerard | officer: General Counsel | 6.6K | 0.00% | Jan 21, 2026 |
| Catherine Bollard | director | 5.4K | 0.00% | Jan 21, 2026 |
3 ten-percent owners hold 1.49M shares by Form 4, outside the officers-and-directors figure above · 1 person has not refiled in the last 18 months (50.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 21, 2026 | Michael Gerardofficer: General Counsel | Purchase | 6,600 | $2.27 | 6,600 |
| Jan 21, 2026 | Mark Simondirector | Purchase | 11,061 | $2.28 | 147,205 |
| Jan 21, 2026 | Steven Nichtbergerdirector, officer: President & CEO | Purchase | 45,000 | $2.24 | 1,031,483 |
| Jan 21, 2026 | Catherine Bollarddirector | Purchase | 4,405 | $2.27 | 5,405 |
| Jan 21, 2026 | Steve Gavelofficer: Chief Commercial Officer | Purchase | 22,170 | $2.27 | 22,170 |
| Jan 21, 2026 | Shawn Tomasellodirector | Purchase | 22,725 | $2.21 | 22,725 |
| Jan 21, 2026 | Gwendolyn Binderofficer: President, Science & Tech. | Purchase | 11,312 | $2.19 | 31,312 |
| Jan 21, 2026 | David J. Changofficer: Chief Medical Officer | Purchase | 8,800 | $2.26 | 8,800 |
CongressHouse and Senate disclosures
Not reported.